Hépatotoxicité des antituberculeux : épidémiologie, mécanisme et conduite à tenir

Tostmann A, Boeree MJ, Aarnoutse RE, et al (2008) Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol 23(2):192–202 Chalasani N, Björnsson E (2010) Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology 138:2246–2259 Teleman MD, Chee CB, Earnest A, Wang YT (2002) Hepatotoxicity of tuberculosis chemotherapy under general programme conditions in Singapore. Int J Tuberc Lung Dis 6:699–705 Wong WM, Wu PC, Yuen MF, et al (2000) Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology 31:201–206 Lee BH, Koh WJ, Choi MS, et al (2005) Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy. Chest 127:1304–1311 PukenyteF E, Lescure X, Rey D, et al (2007) Incidence of and risk factors for severe liver toxicity in HIV-infected patients on antituberculosis treatment. INT J Tubercl Lung Dis 11(1):78–84 Hung Jung C, Wong Jung K, Yong Ju, et al (2007) Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis. Tuberculosis 87:551–556 Cross FS, Long MW, Banner AS, et al (1980) Rifampin-isoniazid therapy of alcoholic and non alcoholic tuberculous patients in a US Public Health Service Cooperative Therapy Trial. Am Rev Respir Dis 122:349–353 Pande JN, Singh SP, Khilnani GC, et al (1996) Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study. Thorax 51:132–136 Jiang Y, Renxiu P (2009) Does CYP2E1 play a major role in the aggravation of isoniazid toxicity by rifampicin in human hepatocytes? Br J Pharmacol 157:331–333 Rumack BH (2002) Acetaminophen hepatotoxicity: The first 35 years. J Toxicol Clin 40:3–20 Watkins P, Seligman PJ, Pears JS, et al (2008) Using controlled clinical trials to learn more about acute drug Induced liver injury. Hepatology 48:1680–1689 Larrey D (2009) Foie, médicaments et agents chimiques. Gastroenterol Clin Biol 33:1136–1146 Kaplowitz N, DeLeve LD (2007) Drug-induced liver disease. Informa healthcare, New York, London Nolam CM, Goldberg SV, Buskin SE (1999) Hepatotoxicity associated with isoniazid preventive therapy. JAMA 281(11):1014–1018 Blumberg HM, Burman WJ, Chaisson RE, et al (2003) American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 167(4):603–662 El Ftouh M, Mouline S, Badsi A, et al (1998) Médicaments antituberculeux: effets secondaires et conduite à tenir. Médecine du Maghreb 67:35–38 Kshirsagar A, Vetal Y, Ashok P, et al (2010) Drug induced hepatotoxicity: a comprehensive review. Internet J Pharmacol 8: 2 Durand F, Bernuan J, Pessayre D, et al (1995) Deleterious influence of pyrazinamide of the outcome of patients with fulminant: subfulminant liver failure during tuberculosis treatment including isoniazid. Hepatology 21(4)929–932 Aouam K, Chaabane A, Ben Rhomdane F, et al (2007) Les effets indésirables des antituberculeux: épidémiologie, mécanismes et conduite à tenir. Med Mal Infect 37:253–261 Knobel B, Buyanowsky G, Dan M, Zaidel L (1997) Pyrazinamidinduced granulomatosis hepatitis. J Clin Gastroenterol 24(4):264–266 Ben Salem C, Chazouillères O (2004) Hépatotoxicité des médicaments 14e mise à jour du fichier bibliographique des atteintes hépatiques et des médicaments responsables. Gastroenterol Clin Biol 28:720–759 Wing-Wai Y, Chi-Chiu L (2007) Antituberculosis drugs and hepatotoxicity. The Hong Kong Medical Diary 12(1):7–9 Abaakil H (2007) Hépatopathies médicamenteuses. Thèse de doctorat en médecine, Casablanca, no 83 Tahooqlu K (2001) The management of antituberculosis drug induced hepatotoxicity. Int J Tuberc Urg Dis 5(1):65–69 An official ATS statement: hepatotoxicity of antituberculosis therapy (2006). Am J Respir Crit Care Med 174:935–952